Real journeys and verified breakthroughs — updated regularly. See why patients from around the world are choosing China, and what's newly possible here.
A New Zealand businessman was told at home he had only months to live and should consider palliative care. He travelled to a Shanghai CAR-T centre, received bridging therapy followed by a CAR-T infusion — and his tumour disappeared within about three months. He has since resumed a normal life.
Reported by Yicai Global, December 2025. Individual outcomes vary and cannot be guaranteed; this story illustrates access, not a promise of results.
For decades patients travelled East-to-West; today patients from the US, UK, Germany, France, Canada & New Zealand travel to China.
China's medical-tourism sector is projected to grow from ~US$1.3B (2025) to US$3.4B (2035), led by advanced cancer care.
China approved satri-cel — the world's first CAR-T cell therapy for a solid tumour (Claudin18.2+ advanced gastric cancer).
Shanghai-developed NEO became the first invasive BCI approved for use beyond clinical trials.
At Huashan Hospital (Fudan University), a man paralysed for 13 years regained mind-control of a computer within weeks.
A China-originated PD-1/VEGF bispecific became the first drug to beat pembrolizumab in Phase 3 lung cancer.
Shanghai recorded 300,000+ international medical-service visits in H1 2024 across 22 top hospitals.
Send us your case for a free, confidential review and a clear plan and quote — with no obligation, in your language.
Free consultation · Reply within 24 hours · Fully confidential